跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
VSIQQ brolucizumab (rbe) 120 mg/mL solution for injection in vial - TGA Drug Approval Details
Approvals
/
TGA
/
VSIQQ brolucizumab (rbe) 120 mg/mL solution for injection in vial
Approved
STANDARD
VSIQQ brolucizumab (rbe) 120 mg/mL solution for injection in vial
Novartis Pharmaceuticals Australia Pty Ltd
🇦🇺 Therapeutic Goods Administration
Approval Date
May 30, 2025
Approval ID
4440bb94cf93f66d
Company
Novartis Pharmaceuticals Australia Pty Ltd
Type
Standard
Approval Details
Approval Id
4440bb94cf93f66d
Product Name
VSIQQ brolucizumab (rbe) 120 mg/mL solution for injection in vial
Artg Id
349910
Artg Name
VSIQQ brolucizumab (rbe) 120 mg/mL solution for injection in vial
Sponsor
Novartis Pharmaceuticals Australia Pty Ltd
Company Detail Path
/organization/novartis-pharmaceuticals-australia-pty-ltd
Artg Date
2021-01-28
Registration Type
Medicine
Therapeutic Good Type
Medicine
Licence Status
A
Licence Category
RE
Active Ingredients
Approved
Quick Info
Agency
TGA
Country
🇦🇺
Approval Date
May 30, 2025
Approval ID
4440bb94cf93f66d
Type
Standard
Back to TGA Approvals
